About Alpha-1B-glycoprotein
Alpha-1B-glycoprotein (A1BG) is a protein
from Homo sapiens identified by UniProt accession
P04217, 495 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | Alpha-1B-glycoprotein |
|---|
| UniProt accession | P04217 |
|---|
| Gene | A1BG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 495 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (87)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.15
- neoplasm · score 0.05
- breast cancer · score 0.04
- Rheumatoid arthritis · score 0.03
- cancer · score 0.02
- oral squamous cell carcinoma · score 0.02
- acute myeloid leukemia · score 0.02
- ulcerative colitis · score 0.02
- multiple myeloma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04217-F1 | alphafold | PREDICTED | 86.47 | — |
Amino-acid sequence (495 residues)
MSMLVVFLLL WGVTWGPVTE AAIFYETQPS LWAESESLLK PLANVTLTCQ AHLETPDFQL FKNGVAQEPV HLDSPAIKHQ FLLTGDTQGR YRCRSGLSTG WTQLSKLLEL TGPKSLPAPW LSMAPVSWIT PGLKTTAVCR GVLRGVTFLL RREGDHEFLE VPEAQEDVEA TFPVHQPGNY SCSYRTDGEG ALSEPSATVT IEELAAPPPP VLMHHGESSQ VLHPGNKVTL TCVAPLSGVD FQLRRGEKEL LVPRSSTSPD RIFFHLNAVA LGDGGHYTCR YRLHDNQNGW SGDSAPVELI LSDETLPAPE FSPEPESGRA LRLRCLAPLE GARFALVRED RGGRRVHRFQ SPAGTEALFE LHNISVADSA NYSCVYVDLK PPFGGSAPSE RLELHVDGPP PRPQLRATWS GAVLAGRDAV LRCEGPIPDV TFELLREGET KAVKTVRTPG AAANLELIFV GPQHAGNYRC RYRSWVPHTF ESELSDPVEL LVAES
Explore Alpha-1B-glycoprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets